Melinda Cail
Family Medicine · Oklahoma City, OKNPI 1609802206
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $80,525 of the $121,687 with a category attached, or 66.2%. Lilly USA, LLC accounts for 62.8% of it on its own, with 54 other manufacturers making up the rest. 2025 is the largest year on record at $46,956, more than ten times the $2,718 reported in 2019. Among family medicine clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 709 payments — averaging $171.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$76K
- Amgen$23K
- Genentech USA, Inc.$11K
- Modernatx, Inc.$2K
- Duchesnay USA Incorporated$2K
- Boehringer Ingelheim$1K
- plus $6K from 49 others
What the payments were for
- Consulting fees$16,94314%
- Speaking & faculty fees$80,52566%
- Travel & lodging$11,73510%
- Food & beverage$12,46110%
- Education$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$121,687 in reported general payments places this provider in the 95th percentile of 1,730 family medicine providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 53 | $60,286 |
| MounjaroTirzepatide | 56 | $57,442 |
| Repatha SureclickEvolocumab | 13 | $7,003 |
| PremarinEstrogens, Conjugated | 12 | $3,058 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 92 | $2,023 |
| Levothyroxine Sodium | 122 | $1,763 |
| Olmesartan Medoxomil | 48 | $1,343 |
| Montelukast Sodium | 35 | $1,051 |
| Rosuvastatin Calcium | 65 | $997 |
| Gabapentin | 38 | $971 |
| Omeprazole | 34 | $928 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 13 | $805 |
| Metoprolol Succinate | 34 | $802 |
| Estradiol | 21 | $798 |
| Duloxetine Hcl | 27 | $792 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $654 | $60,28653 claims |
| Lilly USA, LLCMounjaro | $76,415 | $57,44256 claims |
| PfizerPremarin | $332 | $3,05812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Oklahoma City
- Alexander FrankOklahoma City$3.1M
- Jose Maria Borrego AcostaOklahoma City$106K
- John PittmanOklahoma City$39K
- Terrence TruongOklahoma City$32K
- Jonathon KnoxOklahoma City$20K
- Steven SacketOklahoma City$17K
- Stanley CorleyOklahoma City$16K
- Teddy WebbOklahoma City$15K
- Judy MagnussonOklahoma City$14K
- Ryan GotcherOklahoma City$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.